Payment overview · 2025
General Payments
$464.38
26 reported records · 12 companies
Healthcare provider profile · identity verified
Chip D Holbrook, MD
Allopathic & Osteopathic Physicians|Family Medicine · MENDENHALL, MS · NPI 1962546192
Verified facts
What the public records show
CMS Open Payments records show Chip D Holbrook, MD received $464.38 in general payments during 2025 across 26 reported records.
Lilly USA, LLC accounted for 22.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Farxiga, Jardiance, Ozempic, Trelegy Ellipta, Trintellix, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Ubrelvy by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 272 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 422 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synjardy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 422 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Ozempic by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $104.26 | 22.4% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $88.18 | 19.0% | 5 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $44.62 | 9.6% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $39.57 | 8.5% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $39.16 | 8.4% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $32.74 | 7.0% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $30.31 | 6.5% | 2 | 2025 |
| Purdue Pharma L.P. | Unresolved — no canonical attribution shown | $18.82 | 4.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.16 | 3.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.40 | 3.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.89 | 3.6% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.27 | 3.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $464.38 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $88.18 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $75.05 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $70.20 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $68.78 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $44.62 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $41.09 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $39.16 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $32.74 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $30.31 | 2 | 2025 |
Source payment records
|
|||||
| NALMEFENE HYDROCHLORIDE Normalized: nalmefene hydrochloride |
Drug | Purdue Pharma L.P. | $18.82 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.16 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.40 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.05 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $14.27 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 34 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 272 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 422 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 142 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 86 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
272 | 31 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
422 | 42 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
34 | 33 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
52 | 37 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
86 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
422 | 42 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
142 | 19 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1132 | 180 |
| Amlodipine Besylate | Amlodipine Besylate | 970 | 171 |
| Potassium Chloride | Potassium Chloride | 867 | 162 |
| Gabapentin | Gabapentin | 854 | 127 |
| Furosemide | Furosemide | 796 | 144 |
| Pantoprazole Sodium | Pantoprazole Sodium | 795 | 130 |
| Sertraline Hcl | Sertraline Hcl | 747 | 122 |
| Levothyroxine Sodium | Levothyroxine Sodium | 653 | 87 |
| Eliquis | Apixaban | 562 | 59 |
| Omeprazole | Omeprazole | 562 | 88 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 560 | 95 |
| Tamsulosin Hcl | Tamsulosin Hcl | 518 | 77 |
| Metoprolol Succinate | Metoprolol Succinate | 505 | 90 |
| Metformin Hcl | Metformin Hcl | 490 | 84 |
| Losartan Potassium | Losartan Potassium | 453 | 92 |
| Trazodone Hcl | Trazodone Hcl | 443 | 74 |
| Carvedilol | Carvedilol | 424 | 72 |
| Jardiance | Empagliflozin | 422 | 42 |
| Lisinopril | Lisinopril | 376 | 71 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 375 | 66 |
| Famotidine | Famotidine | 374 | 68 |
| Mirtazapine | Mirtazapine | 363 | 59 |
| Meloxicam | Meloxicam | 316 | 64 |
| Spironolactone | Spironolactone | 309 | 59 |
| Valsartan | Valsartan | 290 | 49 |
| Farxiga | Dapagliflozin Propanediol | 272 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 271 | 48 |
| Quetiapine Fumarate | Quetiapine Fumarate | 271 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 263 | 42 |
| Escitalopram Oxalate | Escitalopram Oxalate | 249 | 41 |
| Donepezil Hcl | Donepezil Hcl | 241 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 222 | 43 |
| Montelukast Sodium | Montelukast Sodium | 217 | 47 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 217 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 216 | 42 |
| Tramadol Hcl | Tramadol Hcl | 209 | 49 |
| Buspirone Hcl | Buspirone Hcl | 207 | 24 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 198 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 191 | 63 |
| Allopurinol | Allopurinol | 182 | 25 |
| Clonazepam | Clonazepam | 179 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 173 | 31 |
| Divalproex Sodium | Divalproex Sodium | 169 | 24 |
| Olanzapine | Olanzapine | 165 | 24 |
| Celecoxib | Celecoxib | 163 | 27 |
| Alprazolam | Alprazolam | 160 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 155 | 27 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 152 | 31 |
| Levetiracetam | Levetiracetam | 149 | 14 |
| Ozempic | Semaglutide | 142 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 134 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 129 | 43 |
| Sucralfate | Sucralfate | 127 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 126 | 23 |
| Metformin Hcl Er | Metformin Hcl | 126 | 23 |
| Risperidone | Risperidone | 120 | 18 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 113 | 84 |
| Memantine Hcl | Memantine Hcl | 112 | 14 |
| Finasteride | Finasteride | 110 | 15 |
| Prednisone | Prednisone | 110 | 59 |
| Temazepam | Temazepam | 108 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 107 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 101 | 25 |
| Estradiol | Estradiol | 99 | 17 |
| Myrbetriq | Mirabegron | 96 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 92 | 19 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 91 | 22 |
| Lorazepam | Lorazepam | 91 | 23 |
| Nystatin | Nystatin | 91 | 30 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 87 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 86 | 22 |
| Primidone | Primidone | 80 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 79 | 15 |
| Tresiba Flextouch U-100 | Insulin Degludec | 79 | 11 |
| Entresto | Sacubitril/Valsartan | 73 | 11 |
| Ezetimibe | Ezetimibe | 72 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 72 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 72 | 13 |
| Topiramate | Topiramate | 72 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 71 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 69 | 43 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 69 | suppressed |
| Fluconazole | Fluconazole | 68 | 29 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 68 | 14 |
| Simvastatin | Simvastatin | 68 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 66 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 66 | 14 |
| Glimepiride | Glimepiride | 66 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 62 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 61 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 61 | 11 |
| Xarelto | Rivaroxaban | 60 | suppressed |
| Atenolol | Atenolol | 59 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 59 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 59 | 16 |
| Warfarin Sodium | Warfarin Sodium | 59 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 58 | 22 |
| Bupropion Hcl Sr | Bupropion Hcl | 56 | suppressed |
| Pregabalin | Pregabalin | 55 | 13 |
| Aripiprazole | Aripiprazole | 53 | suppressed |
| Bupropion Xl | Bupropion Hcl | 52 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 52 | 20 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 52 | 37 |
| Linzess | Linaclotide | 49 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 49 | suppressed |
| Azithromycin | Azithromycin | 48 | 40 |
| Morphine Sulfate Er | Morphine Sulfate | 48 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 48 | 23 |
| Promethazine Hcl | Promethazine Hcl | 47 | 14 |
| Synthroid | Levothyroxine Sodium | 47 | suppressed |
| Trulicity | Dulaglutide | 47 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 45 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 45 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 45 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 45 | suppressed |
| Ketoconazole | Ketoconazole | 44 | 12 |
| Ondansetron Odt | Ondansetron | 44 | 21 |
| Novolog Flexpen | Insulin Aspart | 43 | suppressed |
| Januvia | Sitagliptin Phosphate | 42 | suppressed |
| Glipizide | Glipizide | 41 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 41 | 15 |
| Alendronate Sodium | Alendronate Sodium | 40 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 40 | 31 |
| Symbicort | Budesonide/Formoterol Fumarate | 40 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 39 | suppressed |
| Carbamazepine | Carbamazepine | 38 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 38 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 38 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 36 | 22 |
| Lithium Carbonate | Lithium Carbonate | 35 | suppressed |
| Nitroglycerin | Nitroglycerin | 35 | 14 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 34 | 33 |
| Haloperidol | Haloperidol | 34 | suppressed |
| Levofloxacin | Levofloxacin | 34 | 23 |
| Baclofen | Baclofen | 33 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 33 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 32 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 23 |
| Clonidine Hcl | Clonidine Hcl | 31 | suppressed |
| Lactulose | Lactulose | 31 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 31 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Chlorthalidone | Chlorthalidone | 28 | suppressed |
| Gemtesa | Vibegron | 28 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 27 | suppressed |
| Nifedipine Er | Nifedipine | 27 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 26 | suppressed |
| Movantik | Naloxegol Oxalate | 26 | suppressed |
| Digoxin | Digoxin | 25 | suppressed |
| Glipizide Er | Glipizide | 25 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 25 | suppressed |
| Diazepam | Diazepam | 24 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 24 | suppressed |
| Cilostazol | Cilostazol | 23 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 23 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 22 | suppressed |
| Dutasteride | Dutasteride | 22 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 22 | suppressed |
| Methimazole | Methimazole | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Torsemide | Torsemide | 22 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 21 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 21 | suppressed |
| Novolog | Insulin Aspart | 21 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 21 | suppressed |
| Latanoprost | Latanoprost | 20 | suppressed |
| Methocarbamol | Methocarbamol | 20 | suppressed |
| Novolin R | Insulin Regular, Human | 20 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 16 |
| Lovastatin | Lovastatin | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 16 |
| Calcitriol | Calcitriol | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 14 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Fentanyl | Fentanyl | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 16 | suppressed |
| Ubrelvy | Ubrogepant | 16 | suppressed |
| Corlanor | Ivabradine Hcl | 15 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 15 | suppressed |
| Lubiprostone | Lubiprostone | 15 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 14 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 14 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 14 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 13 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Olanzapine Odt | Olanzapine | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Rivastigmine | Rivastigmine | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Timolol Maleate | Timolol Maleate | 13 | suppressed |
| Trandolapril | Trandolapril | 13 | suppressed |
| Victoza 3-Pak | Liraglutide | 13 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Ertapenem | Ertapenem Sodium | 12 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 12 | 12 |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 11 | 11 |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 11 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Dulera | Mometasone/Formoterol | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | 11 |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $464.38 · 26 records | Lilly USA, LLC | AREXVY, Auvelity, CAPLYTA, FARXIGA, JARDIANCE, Kerendia, MOUNJARO, NALMEFENE HYDROCHLORIDE, Ozempic, REXULTI, Rybelsus, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error